OrbiMed, an investment management firm focused on the healthcare sector, launched a new venture capital fund, Caduceus Private Investments IV, LP, with $550m in limited partner commitments.
Approximately 80% of the new vehicle’s capital is from returning investors, including some of the largest pension plans, endowments, foundations, and sovereign funds globally.
Consistent with its predecessors, the new fund will focus primarily on venture-stage biopharmaceutical and medical device companies located in North America and Europe. It is expected to be invested over a three- to five-year period with individual operations ranging from $10m to $50m.
FinSMEs
22/02/2010